Newborn screening (NBS) for galactosemia is done primarily to detect clinically devastating classical galactosemia due to defective function of galactose-1-phosphate uridyltransferase (GALT); however, several other aetiologies may cause elevated total galactose level in the neonatal samples. This evidence concerns the gene GALT and galactosemia.